GlassScriptPhysician profile
Conar P Fitton
NPI 1316182744
$954,680.21
in general payments reported to CMS, 2019-2025
21 companies · $297K in 2025
The $297K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $15K · 2021: $123K · 2022: $92K · 2023: $95K · 2024: $216K · 2025: $297K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $376K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $148K · Travel and Lodging: $63K · Food and Beverage: $14K · Consulting Fee: $5,860 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $376,473.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $148,362.50 |
| Travel and Lodging | $63,408.59 |
| Food and Beverage | $13,704.21 |
| Consulting Fee | $5,860.00 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $606,938.83 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Genzyme Corporation | $149,693.63 | 2023-2025 | |
| Novo Nordisk INC | $78,361.54 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $63,947.73 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $23,571.46 | 2025 | Iqirvo |
| Abbvie INC. | $22,969.68 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $8,257.92 | 2024-2025 | Dupixent |
| Redhill Biopharma INC. | $176.03 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Medtronic, INC. | $165.50 | 2021 | |
| Covidien LP | $154.22 | 2020 | |
| Exact Sciences Corporation | $119.32 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $117.36 | 2019-2025 | Entyvio |
| Ethicon US, LLC | $92.72 | 2021 | |
| Ironwood Pharmaceuticals, INC | $54.35 | 2019-2020 | |
| Allergan, INC. | $20.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $14.31 | 2021 | |
| Intercept Pharmaceuticals, INC. | $13.28 | 2023 | Ocaliva |
| Kci USA, INC. | $11.75 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conar Fitton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.